Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals.
Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.
Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.
For more information, visit the website or email enquiries@gwt.bio.
Founded date: 2017
Investors 1
| Date | Name | Website |
| 27.01.2023 | Earlybird ... | earlybird.... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 27.01.2023 | British Pa... | 26 January 2023: British Patie... | - | - | britishpat... |